Trial Profile
A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Auriclosene (Primary)
- Indications Gram-positive infections; Impetigo; Staphylococcal infections; Streptococcal infections
- Focus Therapeutic Use
- Sponsors NovaBay Pharmaceuticals
- 24 Sep 2012 Results have been presented in a Galderma media release.
- 17 Sep 2012 Results were published in the International Journal of Clinical and Experimental Pathology (IJCEP), according to a NovaBay media release
- 09 Jun 2011 Additional source identified and integrated: ClinicalTrials.gov.